tradingkey.logo

ANI Pharmaceuticals Inc

ANIP
查看詳細走勢圖
82.850USD
+0.020+0.02%
收盤 12/19, 16:00美東報價延遲15分鐘
1.86B總市值
48.51本益比TTM

ANI Pharmaceuticals Inc

82.850
+0.020+0.02%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+0.02%

5天

+3.06%

1月

+3.14%

6月

+28.13%

今年開始到現在

+49.87%

1年

+52.69%

查看詳細走勢圖

TradingKey ANI Pharmaceuticals Inc股票評分

單位: USD 更新時間: 2025-12-19

操作建議

ANI Pharmaceuticals Inc當前公司基本面數據相對健康,增長潛力很大。當前估值合理,在藥品行業排名3/158位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價108.00。中期看,股價處於下降通道。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

ANI Pharmaceuticals Inc評分

相關信息

行業排名
3 / 158
全市場排名
20 / 4582
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 9 分析師
買入
評級
108.000
目標均價
+32.78%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

ANI Pharmaceuticals Inc亮點

亮點風險
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
業績高增長
公司營業收入穩步增長,連續3年增長94.19%
業績轉虧
公司業績轉虧,最新年度虧損美元
估值高估
公司最新PE估值48.52,處於3年歷史高位
機構加倉
最新機構持股21.97M股,環比增加0.07%
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉1.27M股
活躍度增加
近期活躍度增加,過去20天平均換手率1.66

ANI Pharmaceuticals Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

ANI Pharmaceuticals Inc簡介

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
公司代碼ANIP
公司ANI Pharmaceuticals Inc
CEOLalwani (Nikhil Suresh)
網址https://www.anipharmaceuticals.com/

常見問題

ANI Pharmaceuticals Inc(ANIP)的當前股價是多少?

ANI Pharmaceuticals Inc(ANIP)的當前股價是 82.850。

ANI Pharmaceuticals Inc 的股票代碼是什麼?

ANI Pharmaceuticals Inc的股票代碼是ANIP。

ANI Pharmaceuticals Inc股票的52週最高點是多少?

ANI Pharmaceuticals Inc股票的52週最高點是99.500。

ANI Pharmaceuticals Inc股票的52週最低點是多少?

ANI Pharmaceuticals Inc股票的52週最低點是52.500。

ANI Pharmaceuticals Inc的市值是多少?

ANI Pharmaceuticals Inc的市值是1.86B。

ANI Pharmaceuticals Inc的淨利潤是多少?

ANI Pharmaceuticals Inc的淨利潤為-20.15M。

現在ANI Pharmaceuticals Inc(ANIP)的股票是買入、持有還是賣出?

根據分析師評級,ANI Pharmaceuticals Inc(ANIP)的總體評級為買入,目標價格為108.000。

ANI Pharmaceuticals Inc(ANIP)股票的每股收益(EPS TTM)是多少

ANI Pharmaceuticals Inc(ANIP)股票的每股收益(EPS TTM)是1.708。
KeyAI